Quick-Med Technologies Awarded NSF Grant to Develop Antimicrobial Coatings That Can Be

GAINESVILLE, FL--(Marketwired - May 30, 2013) - Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded grant IIP-1315379 by the National Science Foundation (NSF), titled: "Regenerable Antimicrobial Coatings Containing Zinc Oxide Binders for Hydrogen Peroxide Cleaning Solutions." Quick-Med's Stay Fresh® technology was competitively selected for this award under the Small Business Innovation Research (SBIR) program of NSF. The SBIR program, established by the U.S. Congress, supports scientific excellence and technological innovation through the investment of federal research funds by competitively awarding contracts and grants on the basis of scientific merit, commercial potential, and potential for societal impact by the supported research.

The Phase I objective of this research is to develop Regenerable Antimicrobial Coatings with long-lasting efficacy for use in medical instruments, devices, and hospital equipment and facilities. The same coatings will also have broad utility in the consumer, industrial, and institutional markets.

The coating technology is an extension of the highly effective Stay Fresh technology, sequestering Hydrogen Peroxide (HP) in zinc oxide particles incorporated into the coatings. Exposure of coated surfaces to commercially-available HP-containing cleaning products will cause binding of HP to the zinc oxide particles -- allowing HP to be sequestered within the coating after the surface has dried. This technology is designed to provide durable and long-lasting antimicrobial effect sufficient to reduce or eliminate the proliferation and spread of pathogenic organisms in between cleaning cycles. Additionally, the antimicrobial effect should be regenerated each time the surface is cleaned with peroxide-containing cleaning products.

The Phase I research grant is valued at about $150,000, and the performance period is from July 1, 2013 through December 31, 2013. The Phase 1 award also qualifies Quick-Med to apply for Phase 2, which can bring the total value close to $1M, and will develop the proof of concept to commercial readiness. "We are very pleased to have been competitively selected for this important advanced research program to develop antimicrobial coatings," said Bernd Liesenfeld, Quick-Med's President. "This award is a great validation of our Stay Fresh antimicrobial technology platform and will enable us to continue our development of products that help prevent microbial contamination, and pathogen transfer, particularly as focused on healthcare settings. We believe that this technology can be particularly helpful to aid infection control strategies in institutions housing vulnerable populations."

About Stay Fresh Stay Fresh is Quick-Med's newest technology platform. This technology is based on hydrogen peroxide -- a well known consumer antimicrobial product that is commonly utilized in households for disinfecting cuts, scrapes, toothbrushes and more. Hydrogen peroxide is also produced by human cells to combat invasive bacteria, and is a naturally occurring preservative component of milk and honey. EPA has registered Stay Fresh to protect a broad selection of treated goods for consumer use, including textiles, decorative fabrics, and functional fabrics such as filters and carpets. FDA has granted clearance to market an antibacterial medical textile based on Stay Fresh technology. The Stay Fresh technology offerings provided by Quick-Med are expanding continuously, with development of further applications including antimicrobial surface treatments, and superabsorbent antimicrobial powders to complement the range of products that are already cleared for consumer use under EPA or FDA jurisdiction.

About Quick-Med Technologies, Inc. Quick-Med Technologies, Inc. is a life sciences company that is developing and commercializing proprietary, broad-based technologies for the consumer and healthcare markets. The Company's NIMBUS® technology is the first FDA-cleared, non-leaching antimicrobial technology available in a wound dressing. Its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications. Quick-Med develops antimicrobial technologies to promote public health, safety and comfort. For more information, see: www.quickmedtech.com.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

CONTACT: Quick-Med Technologies Bernd LiesenfeldPresident (352) 379-0611 bliesenfeld@quickmedtech.com

Quick Med Technologies (CE) (USOTC:QMDT)
Historical Stock Chart
From Apr 2024 to May 2024